CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸
CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:T7 Peptide-modified macrophage membrane-coated nanoplatform for enhanced glioma treatment.
T7 Peptide-modified macrophage membrane-coated nanoplatform for enhanced glioma treatment.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
将静脉化疗药物高效、安全地跨越血脑屏障(BBB)递送至脑肿瘤的精确位置,是胶质瘤治疗中的关键环节。在此,我们介绍一种仿生纳米平台(T7-M-C/S),其核心由盐酸伊立替康(CPT11)及其生物活性代谢物7-乙基-10-羟基喜树碱(SN38)组成,外层包裹一层T7肽修饰的巨噬细胞膜。CPT11与SN38自发组装成稳定且水分散性的纳米颗粒(C/S),极大提高了SN38的水溶性。修饰肽与巨噬细胞表达的固有蛋白的整合赋予该纳米平台增强的生物利用度和强大的胶质瘤靶向能力,最终产生优越的治疗效果。这些发现突出了一种具有高载药能力的药物递送系统,利用巨噬细胞膜,并展现出治疗胶质瘤的巨大潜力。
The efficient and secure delivery of intravenous chemotherapeutic agents across the blood-brain barrier (BBB) to the precise location of a brain tumor is a crucial element in glioma treatment.
Herein, we introduce a biomimetic nanoplatform (T7-M-C/S) comprising a core made up of irinotecan hydrochloride (CPT11) and its bioactive metabolite, 7-Ethyl-10-hydroxycamptothecin (SN38), surrounded by a layer of T7-peptide-modified macrophage membrane. CPT11 spontaneously assembles with SN38 into stable and water-dispersible nanoparticles (C/S), greatly enhancing the water solubility of SN38.
The integration of the modified peptide with the inherent proteins expressed by macrophage cells confers the nanoplatform with enhanced bioavailability and robust glioma-targeting abilities, ultimately resulting in superior therapeutic outcomes. These discoveries highlight a drug delivery system characterized by a high drug loading capacity, leveraging the macrophage membrane, and promising significant potential for glioma treatment.
MEMBER ACCOUNT
登录成功会直接打开下一页。